Help | RSS Feed

Nektar Therapeutics (NASD:NKTR) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Nektar Therapeutics (NASD:NKTR) seasonal charts above shows that a Buy Date of November 6 and a Sell Date of March 13 has resulted in a geometric average return of 13.35% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 15 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 28% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system’s natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body’s self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

To download NKTR seasonal chart data, please log in or Subscribe.


Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z